Gralinski M R, Rowse P E, Breider M A
Department of Pathology and Experimental Toxicology, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA.
J Cardiovasc Pharmacol. 1998 Jun;31(6):909-13. doi: 10.1097/00005344-199806000-00015.
We examined whether troglitazone and pioglitazone, antidiabetic thiazolidinediones, would directly induce endothelial cell proliferation or influence cytokine-driven proliferation in vitro. Monolayers of Balb/c mouse aortic endothelial cells were treated with troglitazone or pioglitazone in the absence of fetal bovine serum. Endothelial cells also were exposed to varying concentrations of basic fibroblast growth factor (bFGF) or insulin with or without either thiazolidinedione. After 48 h, 3-[4,5-dimethylthiozol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assays were performed to quantitate endothelial cell proliferation by using the various treatment regimens. The data demonstrate that the antidiabetic thiazolidinediones troglitazone and pioglitazone negligibly affect direct endothelial cell proliferation in vitro. Furthermore, troglitazone and pioglitazone significantly inhibit bFGF-induced endothelial cell mitogenesis, whereas only high concentrations of troglitazone affect insulin-mediated proliferation.
我们研究了抗糖尿病噻唑烷二酮类药物曲格列酮和吡格列酮是否会在体外直接诱导内皮细胞增殖或影响细胞因子驱动的增殖。在无胎牛血清的情况下，用曲格列酮或吡格列酮处理Balb/c小鼠主动脉内皮细胞单层。内皮细胞还暴露于不同浓度的碱性成纤维细胞生长因子（bFGF）或胰岛素，同时或不同时添加噻唑烷二酮类药物。48小时后，采用3-[4,5-二甲基噻唑-2-基]-2,5-二苯基溴化四氮唑（MTT）法，通过各种处理方案定量内皮细胞增殖。数据表明，抗糖尿病噻唑烷二酮类药物曲格列酮和吡格列酮在体外对内皮细胞直接增殖的影响可忽略不计。此外，曲格列酮和吡格列酮显著抑制bFGF诱导的内皮细胞有丝分裂，而只有高浓度的曲格列酮影响胰岛素介导的增殖。
